Last €68.12 EUR
Change Today -0.15 / -0.22%
Volume 409.3K
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

ucb sa (UCB) Snapshot

Open
€68.50
Previous Close
€68.27
Day High
€68.77
Day Low
€68.01
52 Week High
08/29/14 - €75.62
52 Week Low
09/26/13 - €42.06
Market Cap
13.2B
Average Volume 10 Days
287.7K
EPS TTM
€1.34
Shares Outstanding
194.5M
EX-Date
04/29/14
P/E TM
50.8x
Dividend
€1.04
Dividend Yield
1.53%
Current Stock Chart for UCB SA (UCB)

Related News

No related news articles were found.

ucb sa (UCB) Related Businessweek News

No Related Businessweek News Found

ucb sa (UCB) Details

UCB S.A., a biopharmaceutical company, discovers and develops therapies primarily for central nervous system (CNS) disorders and immunology diseases worldwide. Its CNS products include Vimpat and Keppra for epilepsy, and Neupro for Parkinson’s disease and restless legs syndrome; Nootropil for regulating cerebral functions; and Metadate CD for attention deficit hyperactivity disorder. The company is developing Vimpat, which is under Phase III clinical trials for epilepsy-monotherapy; and brivaracetam for epilepsy-adjunctive therapy, as well as developing Vimpat that has completed Phase II clinical trials for epilepsy-paediatric adjunctive therapy, and epilepsy adjunctive therapy. It is also developing UCB0942, which has completed Phase I clinical trials for refractory epilepsy. The company provides immunology products, such as Cimzia for Crohn's disease and rheumatoid arthritis; Xyzal and Zyrtec for allergies; Tussionex for respiratory disease; and Lortab for pain relief. It is also developing CDP7657 that has completed Phase I clinical trials for systemic lupus erythematosus; and UCB4940, which is under Phase I clinical trial for immunological diseases. The company has a strategic collaboration with Five Prime Therapeutics, Inc. for the discovery of biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases and CNS disorders; and a strategic partnership with Sanofi for the discovery and development of anti-inflammatory small molecules. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,224 Employees
Last Reported Date: 02/28/14
Founded in 1928

ucb sa (UCB) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €2.1M
Compensation as of Fiscal Year 2013.

ucb sa (UCB) Key Developments

UCB Announces U.S. Food and Drug Administration Approves Supplemental New Drug Application (sNDA) for VIMPAT(R) (lacosamide) C-V

UCB announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VIMPAT(R) (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.(1) This is a new indication for VIMPAT(R) which is already approved in the U.S. as adjunctive treatment for partial-onset seizures in patients in this age group.(1) This new indication means that adults with partial-onset seizures can be initiated on VIMPAT(R) monotherapy, and patients already on an anti-epileptic drug can be converted to VIMPAT(R) monotherapy. UCB also announced that the FDA has approved a new single loading dose administration option for all formulations of VIMPAT(R), when used as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. VIMPAT(R) Monotherapy: The new U.S. monotherapy approval for VIMPAT(R) is based on a Phase 3 historical-control conversion to lacosamide monotherapy study in adult epilepsy patients with partial-onset seizures.(1) The study met its primary endpoint, demonstrating that the exit percentage, defined as the estimated percentage of patients meeting pre-defined exit criteria, for patients converting to lacosamide 400 mg/day was significantly lower than the historical control exit percentage, used as a comparator. Lacosamide 300 mg/day also met the pre-specified criteria for efficacy. The most common adverse reactions in the monotherapy study were similar to those seen in adjunctive therapy studies; however, one adverse reaction, insomnia, was observed at a rate of greater than or equal to 2% and was not reported at a similar rate in previous studies. Insomnia has also been observed in postmarketing experience. Because this study did not include a placebo control group, causality could not be established. In adjunctive therapy studies, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were dizziness, headache, nausea and diplopia. Additional important safety information for VIMPAT(R) in the U.S. is available below.(1) VIMPAT(R) Single Loading Dose: The new single loading dose administration option for VIMPAT(R) as monotherapy or adjunctive treatment of partial-onset seizures in adults with epilepsy allows the initiation of VIMPAT(R) as a single loading dose of 200 mg (oral or injection), followed approximately 12 hours later by a 100 mg twice daily dose (200 mg/day). The most common loading dose adverse events (greater than or equal to 5%) were dizziness, headache, paraesthesia and gait disturbance. The loading dose should be administered with medical supervision considering the VIMPAT(R) pharmacokinetics and increased incidence of CNS adverse reactions. VIMPAT(R) in the European Union: In the European Union, VIMPAT(R) is approved as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in adult and adolescent (16-18 years) patients with epilepsy. VIMPAT(R) may also be initiated with a single loading dose of 200 mg, followed approximately 12 hours later by a 100 mg twice daily (200 mg/day) maintenance dose regimen. Additional important information on VIMPAT(R) loading dose in the European Union is available below. VIMPAT(R) is not approved in the European Union as monotherapy.

UCB Reports Earnings Results for the First Six Months of 2014; Provides Earnings Guidance for the Year 2014

UCB reported earnings results for the first six months of 2014. The firm has posted a revenue increase of 6% year on year to total EUR 1.757 million and net sales growth of 7% year on year over the period to attain EUR 1.562 billion. The good performance reported by the producer has been mainly fuelled by significant sales increases in its core products, which combined garnered EUR 672 million in sales, corresponding to an average sales increase of 25% year on year. Recurring EBIT was EUR 274 million compared to EUR 178 million a year ago. Operating profit was EUR 227 million compared to EUR 159 million a year ago. Profit before income taxes was EUR 160 million compared to EUR 87 million a year ago. Profit from continuing operations was EUR 112 million compared to EUR 65 million a year ago. Net profit attributable to company shareholders was EUR 137 million or EUR 0.72 per non-diluted share compared to EUR 59 million or EUR 0.32 per non-diluted share a year ago. Recurring EBITDA was EUR 391 million compared to EUR 303 million a year ago. Capital expenditures (including intangible assets) were EUR 91 million compared to EUR 152 million a year ago. Net financial debt was EUR 1,729 million compared to EUR 2,000 million a year ago. Cash flow from operating activities was EUR 174 million compared to EUR 2 million a year ago. Core EPS was EUR 1.22 per share compared to EUR 0.70 per share a year ago. For the year, the company has not changed its outlook for this year, as it expects to attain approximately EUR 3.5 billion to EUR 3.6 billion over the year. Meanwhile, recurring EBITDA is forecast to increase to EUR 740 million-EUR 770 million. Furthermore, UCB said it anticipates Cimzia, Vimpat, and Neupro will continue to drive its revenues in the second quarter. The company, therefore, will continue to significantly invest in these product to favour their further expansion globally. The company expects core earnings per share in the range of EUR 1.90- EUR 2.05.

MC10 Inc. and UCB Partner for Innovative Solutions for Patients with Neurological Disorders

MC10 Inc. and UCB announced that they have entered into a partnership to develop MC10's Biostamp platform for patient-focused disease management solutions. The collaboration will evaluate the integration of MC10's novel, conformal sensing platform with UCB's pharmaceutical products to make a positive difference in the lives of people living with severe neurological disorders. MC10 develops stretchable, electronic sensing systems that bend, flex, and twist to match the properties of the human body. MC10's Biostamp platform offers a unique, patient-friendly solution for disease monitoring and management. This passive monitoring of patient health data will not only help patients but also doctors to provide more personalized care. Additionally, it could help to accelerate neuroscience clinical research and provide insight into the real world impact of therapies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €68.12 EUR -0.15

UCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €33.12 EUR +0.12
Hospira Inc $53.85 USD +0.34
K+S AG €24.26 EUR +0.105
Mylan Inc/PA $47.36 USD -1.07
Valspar Corp/The $80.58 USD +0.10
View Industry Companies
 

Industry Analysis

UCB

Industry Average

Valuation UCB Industry Range
Price/Earnings 42.2x
Price/Sales 3.5x
Price/Book 2.5x
Price/Cash Flow 43.6x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.